Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum
Program Overview
This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.
Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
Identify risk factors and emerging therapies for resistant CMV disease
Activity Faculty
Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY
Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA